Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Оптимизация терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска
Оптимизация терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Заключение Совета экспертов
Всероссийского научного Общества Кардиологов (ВНОК); Национального Общества по изучению Атеросклероза (НОА); Российского общества кардиосоматической реабилитации и вторичной профилактики (РосОКР); Национальной ассоциации по борьбе с инсультами (НАБИ).
Society of cardiology of Russian Federation (VNOK); National Atherosclerosis Society (NAS); Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RosOCR); National Stroke Association (NABI)
Всероссийского научного Общества Кардиологов (ВНОК); Национального Общества по изучению Атеросклероза (НОА); Российского общества кардиосоматической реабилитации и вторичной профилактики (РосОКР); Национальной ассоциации по борьбе с инсультами (НАБИ).
________________________________________________
Society of cardiology of Russian Federation (VNOK); National Atherosclerosis Society (NAS); Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RosOCR); National Stroke Association (NABI)
Полный текст
Список литературы
1. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и соавт. (от имени исследователей) Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование ПЕРСПЕКТИВА (Ч. I). Кардиоваск. тер. и профилакт. 2010; 6: 47–56.
2. Бубнова М.Г., Аронов Д.М. и соавт. (от имени участников программы) Эффективность и безопасность терапии Флувастатином Форте у пожилых – открытое Российское наблюдение и анализ приверженности пациентов терапии статинами: программа ЭФФОРТ CardioСоматика (Кардиосоматика). 2011; 4 (3): 13–22.
3. Кухарчук В.В. и соавт. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации ВНОК. М., 2009.
4. Оганов Р.Г. Кухарчук В.В. Аронов Д.М. и соавт. Заключение экспертов Всероссийского на-учного общества кардиологов, Национального общества по изучению атеросклероза, Рос-сийского общества кардиосоматической реабилитации и вторичной профилактики по опти-мизации терапии статинами в клинической практике. Кардиоваск. тер.и профилакт. 2011; 10 (2).
5. Amarenco P et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2006; 355: 549–59.
6. Amarenco P et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke 2009; 40: 1405–9.
7. Anderson JL et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. JACC 2007; 50 (7): e1–157.
8. Antman EM et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2004; 110: e82–292.
9. Athyros VG et al. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010; 9 (4): 667–74.
10. Athyros V G et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916–22.
11. Bruckert E et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperli-pidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (6): 403–14.
12. Baigent C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet 2010; 376: 1670–81.
13. Camm J et al. Unstable angina and NSTEMI The early management of unstable angina and non-ST-segment-elevation myocardial infarction. NICE clinical guideline. March 2010.
14. Cannon CP et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004; 350: 1495–504.
15. Caterina RD et al. Cholesterol-Lowering Interventions and Stroke Insights From a Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2010; 55: 198–211.
16. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
17. Colivicchi et al. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011; 152 (1): 56–60.
18. Collins R et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
19. Daskalopoulou SS et al. Discontinuation of statin therapy following an acute myocardial infarc-tion: a population-based study. European Heart J 2008; 29: 2083–91.
20. Durazzo AE et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967–75.
21. Farmer JA et al. The Heart Protection Study: Expanding the Boundaries for High-Risk Coronary Disease Prevention. Am J Cardiol 2003; 92 (Suppl.): 3i–9.
22. Foster T et al. Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2010; 106: 71–7.
23. FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury, 2011.
24. FDA drug safety communication: CRESTOR (ZD4522, rosuvastatin calcium) TABLETS FDA Advisory Committee Meeting Briefing Document NDA 21-366 for the use of CRESTOR. 2003.
25. Furie KL et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Asso-ciation Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart As-sociation/Am Stroke Association. Stroke 2011; 42: 227–76.
26. Gorelick Ph. Statin Use and Intracerebral Hemorrhage Evidence for Safety in Recurrent Stroke Prevention? Arch neurol; 12.
27. Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. ESC Guidelines. Eur Heart J 2011. Published online.
28. Hindler K et al. Improved postoperative outcomes associated with preoperative statin therapy Anesthesiol 2006; 105: 1260–72.
29. Hillis LD et al. 2011 ACCF/AHA Guidelines for Coronary Artery Bypass Graft Surgery. JACC 2011; 58 (24). Published online.
30. Khush KK et al. Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure Subgroup Analysis of the Treating to New Targets (TNT) Study. Circulation 2007; 115: 576–83.
31. Koren MJ et al. Clinical Outcomes in Managed-Care Patients With Coronary Heart Disease reated Aggressively in Lipid-Lowering Disease Management Clinics The ALLIANCE Study. J Am Coll Cardiol 2004; 44: 1772–9.
32. Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). J Am Coll Cardiol 2009; 54: 2205–41.
33. LaRosa J et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. TNT Study N Engl J Med 2005; 352: 1425–35.
34. Levine GN et al. ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention. JACC 2011; 58 (24). Published online.
35. Merck. US prescribing information for simvastatin revised to include new limits on the use of the highest dose 80 mg and updated drug interaction information. 2011.
36. Newman CB et al. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am J Cardiol 2003; 92: 670–6.
37. Newman CB et al. Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. Am J Cardiol 2006; 97: 61–7.
38. Nicholls SJ et al. Impact of statins on progression of atherosclerosis: rationale and design of SA-TURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research & Opinion 2011; 27 (6): 1119–29.
39. Nissen SE et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Pro-gression of Coronary Atherosclerosis. JAMA 2004; 291: 1071–80.
40. Patti G et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol 2007; 49: 1272–8.
41. Patti G et al. Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) Study. Circulation 2006; 114: 1455–61.
42. Pedersen TR et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005; 294: 2437–45.
43. Pitt B et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6.
44. Poldermans D et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769–812.
45. Preiss D et al. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. A Meta-analysis. JAMA 2011; 305 (24): 2556–64.
46. Reiner Z et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
47. Rooke TW et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). JACC 2011; 58 (19):
48. Ryden L et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88–136.
49. Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet Published online 2010.
50. Schouten O et al. Fluvastatin XL use is associated with improved cardiac outcome after major vascular surgery. Results from a randomized placebo controlled trial: DECREASE III. Eur Heart J 2008; 29 (abstract supplement) (Hotline session ESC).
51. Schwartz GG et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes The MIRACL Study: A Randomized Controlled Trial. JAMA 2001; 285 (13): 1711–8.
52. Sciascio G et al. Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Under-going Percutaneous Coronary Intervention Results of the ARMYDA-RECAPTURE. J Am Coll Cardiol 2009; 54: 558–65.
53. Sett AK et al. Current status of statin therapy for stroke prevention. Expert Rev Cardiovasc Ther 2011; 9 (10). Published online.
54. Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
55. Shepherd J et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recom-mended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–6.
56. Smith SC et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation 2011; 124.
57. Standards of Medical Care in Diabetes-2011. Diabetes care 2011; 34 (Suppl. 1): S1–61.
58. Tendera M et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. ESC Guidelines 2011.
59. Thielmann M et al. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134: 1143–9.
60. Van de Werf F et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909–45.
61. Vasilios G et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Current Medical Research & Opinion 2004; 20 (5): 627–37.
62. Wijns W et al. Guidelines on myocardial revascularization The Task Force on Myocardial Revas-cularization of the European Society of Cardiology (ESC) and the European Association for Car-dio-Thoracic Surgery (EACTS). Eur Heart J ESC Guidelines 2010. Published online.
63. Wright SR et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guide-line). J Am Coll Cardiol 2011; 57: 1920–59.
2. Бубнова М.Г., Аронов Д.М. и соавт. (от имени участников программы) Эффективность и безопасность терапии Флувастатином Форте у пожилых – открытое Российское наблюдение и анализ приверженности пациентов терапии статинами: программа ЭФФОРТ CardioСоматика (Кардиосоматика). 2011; 4 (3): 13–22.
3. Кухарчук В.В. и соавт. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации ВНОК. М., 2009.
4. Оганов Р.Г. Кухарчук В.В. Аронов Д.М. и соавт. Заключение экспертов Всероссийского на-учного общества кардиологов, Национального общества по изучению атеросклероза, Рос-сийского общества кардиосоматической реабилитации и вторичной профилактики по опти-мизации терапии статинами в клинической практике. Кардиоваск. тер.и профилакт. 2011; 10 (2).
5. Amarenco P et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2006; 355: 549–59.
6. Amarenco P et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke 2009; 40: 1405–9.
7. Anderson JL et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. JACC 2007; 50 (7): e1–157.
8. Antman EM et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2004; 110: e82–292.
9. Athyros VG et al. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010; 9 (4): 667–74.
10. Athyros V G et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916–22.
11. Bruckert E et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperli-pidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19 (6): 403–14.
12. Baigent C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. Lancet 2010; 376: 1670–81.
13. Camm J et al. Unstable angina and NSTEMI The early management of unstable angina and non-ST-segment-elevation myocardial infarction. NICE clinical guideline. March 2010.
14. Cannon CP et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004; 350: 1495–504.
15. Caterina RD et al. Cholesterol-Lowering Interventions and Stroke Insights From a Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2010; 55: 198–211.
16. Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
17. Colivicchi et al. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol 2011; 152 (1): 56–60.
18. Collins R et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
19. Daskalopoulou SS et al. Discontinuation of statin therapy following an acute myocardial infarc-tion: a population-based study. European Heart J 2008; 29: 2083–91.
20. Durazzo AE et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967–75.
21. Farmer JA et al. The Heart Protection Study: Expanding the Boundaries for High-Risk Coronary Disease Prevention. Am J Cardiol 2003; 92 (Suppl.): 3i–9.
22. Foster T et al. Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial. Am J Gastroenterol 2010; 106: 71–7.
23. FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury, 2011.
24. FDA drug safety communication: CRESTOR (ZD4522, rosuvastatin calcium) TABLETS FDA Advisory Committee Meeting Briefing Document NDA 21-366 for the use of CRESTOR. 2003.
25. Furie KL et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Asso-ciation Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart As-sociation/Am Stroke Association. Stroke 2011; 42: 227–76.
26. Gorelick Ph. Statin Use and Intracerebral Hemorrhage Evidence for Safety in Recurrent Stroke Prevention? Arch neurol; 12.
27. Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. ESC Guidelines. Eur Heart J 2011. Published online.
28. Hindler K et al. Improved postoperative outcomes associated with preoperative statin therapy Anesthesiol 2006; 105: 1260–72.
29. Hillis LD et al. 2011 ACCF/AHA Guidelines for Coronary Artery Bypass Graft Surgery. JACC 2011; 58 (24). Published online.
30. Khush KK et al. Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure Subgroup Analysis of the Treating to New Targets (TNT) Study. Circulation 2007; 115: 576–83.
31. Koren MJ et al. Clinical Outcomes in Managed-Care Patients With Coronary Heart Disease reated Aggressively in Lipid-Lowering Disease Management Clinics The ALLIANCE Study. J Am Coll Cardiol 2004; 44: 1772–9.
32. Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). J Am Coll Cardiol 2009; 54: 2205–41.
33. LaRosa J et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. TNT Study N Engl J Med 2005; 352: 1425–35.
34. Levine GN et al. ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention. JACC 2011; 58 (24). Published online.
35. Merck. US prescribing information for simvastatin revised to include new limits on the use of the highest dose 80 mg and updated drug interaction information. 2011.
36. Newman CB et al. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients. Am J Cardiol 2003; 92: 670–6.
37. Newman CB et al. Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 Patients. Am J Cardiol 2006; 97: 61–7.
38. Nicholls SJ et al. Impact of statins on progression of atherosclerosis: rationale and design of SA-TURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research & Opinion 2011; 27 (6): 1119–29.
39. Nissen SE et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Pro-gression of Coronary Atherosclerosis. JAMA 2004; 291: 1071–80.
40. Patti G et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol 2007; 49: 1272–8.
41. Patti G et al. Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) Study. Circulation 2006; 114: 1455–61.
42. Pedersen TR et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005; 294: 2437–45.
43. Pitt B et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6.
44. Poldermans D et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769–812.
45. Preiss D et al. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. A Meta-analysis. JAMA 2011; 305 (24): 2556–64.
46. Reiner Z et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
47. Rooke TW et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). JACC 2011; 58 (19):
48. Ryden L et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88–136.
49. Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet Published online 2010.
50. Schouten O et al. Fluvastatin XL use is associated with improved cardiac outcome after major vascular surgery. Results from a randomized placebo controlled trial: DECREASE III. Eur Heart J 2008; 29 (abstract supplement) (Hotline session ESC).
51. Schwartz GG et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes The MIRACL Study: A Randomized Controlled Trial. JAMA 2001; 285 (13): 1711–8.
52. Sciascio G et al. Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Under-going Percutaneous Coronary Intervention Results of the ARMYDA-RECAPTURE. J Am Coll Cardiol 2009; 54: 558–65.
53. Sett AK et al. Current status of statin therapy for stroke prevention. Expert Rev Cardiovasc Ther 2011; 9 (10). Published online.
54. Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
55. Shepherd J et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recom-mended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–6.
56. Smith SC et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation 2011; 124.
57. Standards of Medical Care in Diabetes-2011. Diabetes care 2011; 34 (Suppl. 1): S1–61.
58. Tendera M et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. ESC Guidelines 2011.
59. Thielmann M et al. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134: 1143–9.
60. Van de Werf F et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909–45.
61. Vasilios G et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Current Medical Research & Opinion 2004; 20 (5): 627–37.
62. Wijns W et al. Guidelines on myocardial revascularization The Task Force on Myocardial Revas-cularization of the European Society of Cardiology (ESC) and the European Association for Car-dio-Thoracic Surgery (EACTS). Eur Heart J ESC Guidelines 2010. Published online.
63. Wright SR et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guide-line). J Am Coll Cardiol 2011; 57: 1920–59.
Авторы
Президиум Совета экспертов: акад. РАМН Р.Г.Оганов (Москва), акад. РАМН Ю.И.Бузиашвили (Москва), член-кор. РАМН В.В.Кухарчук (Москва), проф. Д.М.Аронов (Москва), проф. С.А.Бойцов (Москва).
Рабочая группа по подготовке текста заключения Совета экспертов к публикации: член-кор. РАМН В.В.Кухарчук (Москва), проф. Д.М.Аронов (Москва), проф. М.Г.Бубнова (Москва), д-р мед. наук А.В.Сусеков (Москва).
Состав Совета экспертов: вед. науч. сотр. Н.М.Ахмеджанов (Москва), проф. М.Г.Бубнова (Москва), проф. А.С.Галявич (Казань), проф. В.С.Гуревич (Санкт-Петербург), проф. А.Б.Гехт (Москва), проф. О.М.Драпкина (Москва), д-р. мед. наук М.В.Ежов (Москва), проф. С.Г.Канорский (Краснодар), проф. Н.А.Козиолова (Пермь), проф. Е.И.Красильникова (Санкт-Петербург), проф. Ю.М.Лопатин (Волгоград), член-кор. РАМН И.В.Медведева (Тюмень), проф. О.Д.Остроумова (Москва), проф. В.А.Парфенов (Москва), проф. Н.Б.Перепеч (Санкт-Петербург), д-р мед. наук И.В.Сергиенко (Москва), проф. Л.В.Стаховская (Москва), д-р мед. наук А.В.Сусеков (Москва), проф. Е.И.Тарловская (Киров), проф. С.Н.Терещенко (Москва), ст. науч. сотр. Э.Ф.Тугеева (Москва), проф. С.В.Шалаев (Тюмень).
Working Group to Prepare Expert Council Resolution Text for Publication: Corr. Member of RAMS V.V.Kukharchuk (Moscow), Prof. D.M.Aronov (Moscow), Prof. M.G.Bubnova (Moscow), A.V.Susekov, MD (Moscow).
Рабочая группа по подготовке текста заключения Совета экспертов к публикации: член-кор. РАМН В.В.Кухарчук (Москва), проф. Д.М.Аронов (Москва), проф. М.Г.Бубнова (Москва), д-р мед. наук А.В.Сусеков (Москва).
Состав Совета экспертов: вед. науч. сотр. Н.М.Ахмеджанов (Москва), проф. М.Г.Бубнова (Москва), проф. А.С.Галявич (Казань), проф. В.С.Гуревич (Санкт-Петербург), проф. А.Б.Гехт (Москва), проф. О.М.Драпкина (Москва), д-р. мед. наук М.В.Ежов (Москва), проф. С.Г.Канорский (Краснодар), проф. Н.А.Козиолова (Пермь), проф. Е.И.Красильникова (Санкт-Петербург), проф. Ю.М.Лопатин (Волгоград), член-кор. РАМН И.В.Медведева (Тюмень), проф. О.Д.Остроумова (Москва), проф. В.А.Парфенов (Москва), проф. Н.Б.Перепеч (Санкт-Петербург), д-р мед. наук И.В.Сергиенко (Москва), проф. Л.В.Стаховская (Москва), д-р мед. наук А.В.Сусеков (Москва), проф. Е.И.Тарловская (Киров), проф. С.Н.Терещенко (Москва), ст. науч. сотр. Э.Ф.Тугеева (Москва), проф. С.В.Шалаев (Тюмень).
________________________________________________
Working Group to Prepare Expert Council Resolution Text for Publication: Corr. Member of RAMS V.V.Kukharchuk (Moscow), Prof. D.M.Aronov (Moscow), Prof. M.G.Bubnova (Moscow), A.V.Susekov, MD (Moscow).
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.